| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q59125770 | Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer |
| Q54491354 | Clinically relevant biomarkers in targeted radiotherapy. |
| Q48316437 | Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma |
| Q47446694 | Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer. |
| Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
| Q38914996 | Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. |
| Q37468265 | Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer |
| Q33907089 | Development of a small animal model to simulate clinical stereotactic body radiotherapy-induced central and peripheral lung injuries. |
| Q35983312 | Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy |
| Q64081214 | Editorial on comparison between stereotactic body radiotherapy and surgery in early stage NCSLC by Scotti |
| Q37090175 | Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution |
| Q50667985 | Evaluation of interfractional variation of the centroid position and volume of internal target volume during stereotactic body radiotherapy of lung cancer using cone-beam computed tomography. |
| Q34381901 | GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms |
| Q49891068 | Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience |
| Q91868558 | Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors |
| Q37301068 | Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy |
| Q35074232 | Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy |
| Q36621168 | Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer |
| Q34771688 | Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy |
| Q47149089 | Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer |
| Q36235727 | LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective |
| Q61804649 | Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes |
| Q38220335 | Novel treatment options in stage I non-small-cell lung cancer |
| Q33826696 | Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors |
| Q35124684 | Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. |
| Q42154657 | Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution |
| Q61804645 | Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy |
| Q37152152 | Prognostic impact of average iodine density assessed by dual-energy spectral imaging for predicting lung tumor recurrence after stereotactic body radiotherapy |
| Q36241814 | Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
| Q38256158 | Radiation pneumonitis after stereotactic radiation therapy for lung cancer |
| Q35200592 | SBRT in operable early stage lung cancer patients. |
| Q30241812 | Specific toxicity after stereotactic body radiation therapy to the central chest : A comprehensive review |
| Q35667829 | Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies |
| Q37652546 | Stereotactic body radiation therapy for centrally-located lung tumors |
| Q60912983 | Stereotactic body radiation therapy for non-small cell lung cancer: A review |
| Q35646076 | Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry |
| Q53054421 | Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. |
| Q61804651 | Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer |
| Q64917835 | Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study. |
| Q26781806 | Stereotactic body radiotherapy in lung cancer: an update |
| Q38374340 | Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence? |
| Q38175120 | Stereotactic body radiotherapy: a critical review for nonradiation oncologists |
| Q35824255 | Stereotactic radiotherapy for early stage non-small cell lung cancer |
| Q26748296 | Surgery versus stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer: less is not more |
| Q48369218 | Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. |
| Q38409012 | Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea |
| Q38227883 | The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metasta |
| Q58584561 | Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy |
| Q39015830 | Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. |
| Q40342856 | What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer? |
| Q38172228 | What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer |